PX1 Research provides reference-grade GHRP-2 synthesized to strict chemical purity standards (>98%) for academic, industrial, and institutional research laboratories. Every lot of our growth hormone secretagogue peptides undergoes rigorous analytical validation, including RP-HPLC, ESI-MS mass spectrometry, and bacterial endotoxin testing, ensuring reliable non-clinical experimental reproducible data.
PX1 Research provides reference-grade GHRP-2 synthesized to strict chemical purity standards (>98%) for academic, industrial, and institutional research laboratories. Every lot of our growth hormone secretagogue peptides undergoes rigorous analytical validation, including RP-HPLC, ESI-MS mass spectrometry, and bacterial endotoxin testing, ensuring reliable non-clinical experimental reproducible data.
If your laboratory needs to buy GHRP-2 for sale, PX1 Research provides analytical-grade Growth Hormone Releasing Peptide-2 engineered specifically for in vitro and preclinical research applications. Synthesized in US-based GMP-compliant facilities, our GHRP-2 features verified purity exceeding 98% by HPLC/MS analysis, batch-specific COAs, endotoxin control under 0.1 EU/mg, and same-day dispatch from our CA and AZ facilities.
Researchers seeking to evaluate ghrelin receptor kinetics, somatotroph signaling, or pulsatile hormone release pathways can obtain fully characterized GHRP-2 research peptides with guaranteed lot-to-lot consistency and complete analytical traceability.
Growth Hormone Releasing Peptide-2 (GHRP-2), chemically designated as D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) class. Featuring a molecular formula of C45H55N9O6 and a molecular weight of 818.0 g/mol, GHRP-2 was engineered as an unnatural peptide analog containing non-proteinogenic D-amino acids (such as D-beta-naphthylalanine and D-phenylalanine) to increase enzymatic resistance against plasma endopeptidases.
Unlike endogenous peptidyl ligands that undergo rapid cleavage in biological matrices, the incorporation of D-stereoisomers in the GHRP-2 sequence enhances structural stability while retaining high binding affinity for central and peripheral receptor sites. Laboratory investigators examining growth hormone secretagogues rely on these structural modifications to ensure prolonged active half-lives during in vitro bioassays and preclinical pharmacological evaluations.
GHRP-2 acts as a potent, synthetic agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), a 7-transmembrane G-protein coupled receptor (GPCR) predominantly expressed in the anterior pituitary gland and hypothalamus. Binding of GHRP-2 to GHS-R1a initiates a conformational change that activates the Gq/11 protein complex, triggering phospholipase C (PLC) cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
The generated IP3 binds to receptors on the endoplasmic reticulum, initiating transient intracellular calcium ion (Ca2+) release into the cytoplasm. Concurrently, DAG activates protein kinase C (PKC). This dual signaling cascade stimulates exocytosis of pre-stored growth hormone granules from pituitary somatotrophs without disrupting basal transcription of other anterior pituitary hormones. In vitro assays demonstrate that GHRP-2 acts synergistically when co-administered with endogenous Growth Hormone-Releasing Hormone (GHRH), as GHRH activates the distinct adenylyl cyclase/cAMP/PKA pathway.
Preclinical studies across rodent models and non-human primates have systematically documented the pharmacological profile of GHRP-2. In vitro primary pituitary cell cultures indicate that GHRP-2 induces a dose-dependent increase in somatotroph intracellular calcium, resulting in robust GH release with higher potentiation per molar concentration than its predecessor, GHRP-6.
In vivo animal models evaluating GHS-R1a secretagogue dynamics show that GHRP-2 administration results in rapid, transient elevations in plasma growth hormone concentrations. Furthermore, preclinical literature highlights that GHRP-2 exhibits moderate activity at central ghrelin receptors regulating orexigenic pathways, though to a lesser extent than GHRP-6. Investigators utilizing our analytical research hub can access comprehensive study profiles detailing how GHRP-2 serves as a baseline tool for investigating receptor crosstalk, metabolic signaling, and pituitary secretagogue responsiveness.
When designing comparative secretagogue protocols, researchers frequently evaluate GHRP-2 alongside related synthetic peptides within the GHS-R agonist class. While all these agents bind to the GHS-R1a receptor, their selectivity profiles, receptor affinities, and secondary hormonal impacts vary significantly in preclinical literature.
GHRP-2 exhibits higher potency for GH release than GHRP-6, requiring lower nanomolar concentrations to achieve equivalent somatotroph depolarization in vitro. However, GHRP-6 demonstrates greater activation of hypothalamic orexigenic pathways in animal models. Conversely, Ipamorelin represents a pentapeptide secretagogue engineered for extreme receptor selectivity; unlike GHRP-2, which can cause mild transient elevations in cortisol and prolactin at high doses in preclinical assays, Ipamorelin displays minimal secondary endocrine activation. Investigators combining GHS-R agonists with GHRH analogs such as CJC-1295 often utilize GHRP-2 to study dual-receptor synergistic mechanisms in isolated pituitary tissue.
To preserve chemical integrity and prevent peptide degradation, strict laboratory handling protocols must be enforced upon receipt of lyophilized GHRP-2. Lyophilized vials should be stored upon arrival at -20°C for short-term projects or -80°C for long-term storage, protected from light and atmospheric moisture.
Reconstitution should be performed under a laminar flow hood using sterile laboratory reagents. Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride Injection, USP, are recommended reconstituting solvents depending on the sensitivity of down-stream assays. Allow the vial to reach room temperature prior to solvent addition to prevent condensation within the container. Gently introduce the solvent along the glass wall of the vial and swirl softly to dissolve; high-shear vortexing or vigorous shaking must be avoided as mechanical force can disrupt the peptide's tertiary solution conformation. Reconstituted solutions are stable at 2°C to 8°C for up to 30 days.
At PX1 Research, every batch of GHRP-2 is produced via automated Solid-Phase Peptide Synthesis (SPPS) using Fmoc/tBu chemistry. Following chain assembly, the crude peptide is cleaved from the resin, deprotected, and subjected to multi-stage preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to remove truncated sequences, deletion peptides, and side-reaction byproducts.
Our manufacturing standards ensure that researchers acquire high-purity research peptides that perform predictably across cell culture, spectroscopic, and chromatographic procedures. Each lot is processed in ISO-certified, GMP-compliant facilities within the United States, maintaining stringent environmental monitoring to limit contamination risks.
PX1 Research enforces an uncompromising testing protocol: no lot of GHRP-2 is released for purchase without passing independent analytical verification by an accredited ISO 17025 third-party laboratory. Every order includes a comprehensive Certificate of Analysis (COA) detailing the exact chemical metrics of the batch.
Analytical validation includes two core testing modalities: Analytical RP-HPLC to establish purity percentage (>98.0%) by measuring peak area ratio under UV detection at 214 nm, and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular mass (818.0 Da) and rule out incorrect sequence isomers. Furthermore, every batch undergoes Chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm bacterial endotoxin levels remain strictly under 0.1 EU/mg, protecting sensitive cell lines from endotoxin-induced inflammatory responses.
Procuring research compounds requires vetting vendors to ensure chemical identity, purity, and batch integrity. Substandard or unverified peptide suppliers frequently distribute material containing residual trifluoroacetic acid (TFA) salts, heavy metals, synthetic side-products, or unaccounted endotoxins that corrupt experimental outcomes.
Principal investigators evaluating suppliers should insist on US-based manufacturing, lot-specific COAs verified by independent ISO 17025 labs (rather than internal, non-verifiable test sheets), and complete lot traceability from synthesis to shipment. PX1 Research sets the industry standard by maintaining full analytical transparency and storing reference samples from every synthesized batch.
PX1 Research streamlines procurement for university departments, contract research organizations (CROs), and private biotechnology facilities. Qualified institutions can buy GHRP-2 for sale directly through our secure online portal or set up dedicated corporate billing via our wholesale institutional portal.
All orders placed Monday through Friday before 2:00 PM PST are packed under climate-controlled conditions and dispatched same-day from our dual distribution nodes in California and Arizona. Lyophilized vials are shipped in protective, tamper-evident packaging to preserve physical stability during transit.
What is GHRP-2 studied for in preclinical research?
GHRP-2 is studied in preclinical settings to investigate GHS-R1a receptor kinetics, calcium-dependent signal transduction in somatotroph cells, pulsatile growth hormone release mechanisms, and secretagogue pharmacology.
What purity level does PX1 Research guarantee for GHRP-2?
PX1 Research guarantees a chemical purity of >98.0% for all GHRP-2 batches, as verified by independent RP-HPLC analysis.
How is the molecular identity of GHRP-2 verified?
Molecular identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), verifying that the observed mass matches the theoretical mass of 818.0 Da.
Are endotoxin test results provided with GHRP-2?
Yes. Every lot of GHRP-2 undergoes Chromogenic LAL testing to ensure endotoxin levels are verified below 0.1 EU/mg.
How should lyophilized GHRP-2 be stored upon receipt?
Lyophilized GHRP-2 should be stored at -20°C for short-term work or -80°C for long-term preservation, protected from light and moisture.
What solvent should be used to reconstitute GHRP-2 for lab assays?
GHRP-2 is commonly reconstituted using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride Injection, USP, depending on specific cell culture or analytical protocols.
What is the difference in binding profile between GHRP-2 and Ipamorelin?
GHRP-2 is a hexapeptide agonist at GHS-R1a that can induce mild transient elevations in cortisol and prolactin at higher concentrations in preclinical models, whereas Ipamorelin is a pentapeptide engineered for extreme selectivity with negligible effect on non-target pituitary hormones.
Where does PX1 Research ship GHRP-2 from?
All PX1 Research compounds are stored in climate-controlled facilities and shipped same-day (Monday through Friday) from our fulfillment centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.